Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey

Erdem H. A., Korkmaz P. E., Caglayan D., TAŞBAKAN M., Yamazhan T., TAŞBAKAN M., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.51, sa.3, ss.912-920, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.3906/sag-2008-33
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.912-920
  • Anahtar Kelimeler: SARS-CoV-2, favipiravir, COVID-19, coronavirus, pandemic, antiviral therapy, CORONAVIRUS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background/aim: The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS-CoV-2 pneumonia. Materials and methods: This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. Results: Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%) patients required treatment for respiratory distress. Thirty-three patients (82.5%) were discharged from the hospital with full recovery, 6 patients (15%) died and 1 case (2.5%) was still at the intensive care unit (ICU) when this paper was written. Conclusion: This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.